SAME INSIGHTFUL CONTENT… NEW 3-DAY VIRTUAL FORMAT…
Note that the content of the Program Agenda below will remain, and be reformatted to accommodate our new 3-day virtual conference platform and schedule. Stay tuned for more details…
Many biopharma CI reports disseminated by the Agency are overly verbose, high-level and lack the substantive actionability required for internal usage – facilitating a seamless cascade to management & leadership.
Today’s workshop will translate classical stylistic business writing techniques including those of Strunk and White to the 21st-century biopharmaceutical CI and Strategy world.
In this workshop, we will facilitate two (2) breakouts during which “raw intelligence learnings” will be synthesized and translated into actionable CI deliverables using PowerPoint writing skills and infographic design techniques.
This Workshop is facilitated by David Alderman, President of Molekule Consulting, a global competitive intelligence and strategy consultancy dedicated to the life sciences and biopharmaceutical verticals. David has deep experience from early-development to late-lifecycle management and beyond within biopharma across the competitive landscape among myriad therapy areas, players and subject matters. David is a Subject Matter Expert on the biopharmaceutical vertical; with a particular focus on competition within branded biopharma, small molecule generics and biosimilars.
Topics we will cover:
• What must be in place to seamlessly transition you CI function from an environment of “business as usual” to “business as usual in an unusual environment”?
• What skills and tools need to be in place to adapt such a dramatic change of doing business?
• What processes work and what pitfalls to avoid?
The audience can expect to be able to participate actively in the “conversation” and contribute to the program
Early in life information on disease area and other new products as well as standard of care is crucial. As you enter into the 5 years preceding launch and Phase III needs become specific: registrational benchmarks, competition in terms of market share, trial and launch strategy.
o When and how should you adapt your CI plan to changing markets?
o What we can learn from tangible examples of primary CI’s impact on a business’s success?
For CI professionals, a machine learning-enabled research portal now can automatically mine and synthesize insights from all manner of documents — including industry news, scientific conference abstracts, primary and secondary market research, and even social media (screening out posts that may contain references to “adverse events”) — saving them valuable time, and zeroing in on the most relevant information needed to inform critical business decisions.
For social media planners, machine learning today can conduct a semantic analysis of keywords in social posts about a topic of interest, which yields clear guidance as to which terms have actual business relevance and are therefore worth investing in. (Consider that, on Twitter, the terms that most frequently co-occur with #cancer all have to do with astrology — #Scorpio, #Pisces, #Ascendant — which is not at all helpful to a pharmaceutical company marketing an anti-cancer drug.)
Attendees at this session will learn:
> the four essential ingredients needed to put machine learning to practical use in pharma CI
> best practices to ensure that your organization can safely use social media for research and marketing
> how one leading pharma company is employing machine learning in its CI efforts today
Individuals and teams will take away trusted data-driven approaches to stay on top of emerging technologies & players – without the inefficient burdens of data science – for everyday curation and sharing of key metrics mined from global patents, technical literature, news, litigation, clinical content and fundraisings.
A broader appreciation will be developed for anticipating the future from available external signals. The discussion will interactively review AI, NLP and machine learning approaches that help whole organizations develop shared competitive viewpoints, while capturing nuances for experts and downstream fact-checking.
Key to this session will be addressing business needs across the lifecycle, whereby participants will:
• Develop an in-depth understanding of how a diverse range of facilitated activities (Rapid Immersion, Threat Assessment and Competitor Simulations) can help deliver strategic and competitive insights within an organization
• Appreciate the importance of leveraging the outcomes of workshops to inform and direct decision making
• Receive hands-on opportunities to apply learnings to a pharma case-study in a learning environment
Using business case studies, real-life experiences and validated theory, the INOVIS team will equip you with a number of go-to techniques that can be rapidly integrated into ongoing CI Practice, whether you’re a seasoned CI professional veteran, or newer to the field.
Specifically this presentation will enable you to:
• Advance your understanding of core Gx/biosimilar market dynamics and corresponding CI solutions
• Set up a best-in-industry Gx/biosimilar regulatory intelligence (RI) and CI tracking program
• Understand Gx / biosimilar product development and entry strategies
If you have an abundance of resources, is deep analytics the right answer? Ms. Saraos has led large CI programs at Roche/Genentech, consulted with various small non-commercialized biotechs, and is now at medium-sized biopharma, Jazz Pharmaceuticals. She will share her perspective on different ways to think about right sizing CI efforts that build trust and confidence with key stakeholders. Ms. Saraos will share types of bad behavior and lessons learned on how to get to a healthy CI place.
Technical Cost Modelling (TCM), a method developed at MIT in the 1980’s has long been the gold standard in benchmarking cost-of-goods sold which is time and resource intensive with a limited shelf-life. Although not as precise as TCM, Dig Worldwide’s bespoke COGIntel method allows rapid and cost effective COG benchmarking analysis that provides “good enough” competitive intelligence for strategic decision making. Performance gaps and areas of advantage or disadvantage become visible verses forgotten.
An illustrative CAR-T case study will form an integral part of the talk to help illustrate Dig Worldwide’s methodology.
Case Study Analysis:
• KOL Mapping – Identify and rank oncologists on Twitter
• Sentiment Analysis – Capture and curate reactions to scientific news
• Contextualize Conference Activity – Visually represent activity related to high-impact data release
By increasing productivity and efficiency, these advancements will enable healthcare systems to provide better care to more patients.
Join this session to learn:
The current state of AI and how it will evolve in the near future
How these technologies are already impacting the pharma professional’s day-to-day
How advancements in AI will impact the pharma industry long term
This strategy has the ability to grow your career faster than anything else you’ve ever seen before.
My name is Salvador Carlucci and I’m the former Global Head of Competitive Intelligence at both Roche and Novartis. With the help of talented team members, we built two of the largest CI teams in the pharmaceutical industry.
Most recently, with an experienced team of pharma executives, we built Atacana, one of the fastest-growing Competitive Intelligence and Strategy agencies in the pharmaceutical industry.
So, what is this secret ‘bridge strategy’ and how can you use it to grow your career?
Simple, come to this talk to learn:
1. The one thing your stakeholder (client) really cares about
2. How to increase your CI resources (budget, headcounts, salary, promotion)
3. How to develop high impact and valuable solutions
In this presentation, I’ll share a fresh framework and approach that is generating a level of success that I never expected. Filled with inspirational stories and practical advice, make sure not to miss this presentation.
• How has it changed care management? Some examples
• Who are the new/emerging voices that should be part of your new intelligence plan?
• Use of masks required: Please bring your own if preferred, but masks and hand sanitizer will also be provided.
• Greetings should be socially distanced: no handshakes, hugs, or kisses, etc.
• Meeting space will accommodate more spacing between attendees.
• The hotel experience will be entirely revamped with specific cleaning protocols.